Literature DB >> 2180597

Bispecific antibody: a tool for diagnosis and treatment of disease.

S Songsivilai1, P J Lachmann.   

Abstract

Antibodies with two distinct binding specificities have great potential for a wide range of clinical applications as targeting agents for in vitro and in vivo immunodiagnosis and therapy, and for improving immunoassays. They have shown great promise for targeting cytotoxic effector cells, delivering radionuclides, toxins or cytotoxic drugs to specific targets, particularly tumour cells. We discuss potential applications of bispecific antibodies, the theoretical basis and problems associated with their production and purification, cell fusion and chemical conjugation techniques, and propose a new manufacturing strategy by genetic engineering. This approach has enormous potential applications for producing tailor-made bispecific antibodies, and will enable widespread clinical uses of these antibodies both for diagnostic purposes and therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180597      PMCID: PMC1534963          DOI: 10.1111/j.1365-2249.1990.tb08089.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  66 in total

1.  Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays.

Authors:  M R Suresh; A C Cuello; C Milstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  Targeted cancer treatment.

Authors:  D M Goldenberg
Journal:  Immunol Today       Date:  1989-09

3.  Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

Authors:  G Jung; C J Honsik; R A Reisfeld; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  A novel strategy for producing chimeric bispecific antibodies by gene transfection.

Authors:  S Songsivilai; P M Clissold; P J Lachmann
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

5.  Cyclic tetramolecular complexes of monoclonal antibodies: a new type of cross-linking reagent.

Authors:  P M Lansdorp; R C Aalberse; R Bos; W G Schutter; E F Van Bruggen
Journal:  Eur J Immunol       Date:  1986-06       Impact factor: 5.532

6.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

7.  Bispecific monoclonal antibodies from hybrid hybridomas.

Authors:  M R Suresh; A C Cuello; C Milstein
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

8.  Hybrid antibody-mediated lysis of virus-infected cells.

Authors:  U D Staerz; J W Yewdell; M J Bevan
Journal:  Eur J Immunol       Date:  1987-04       Impact factor: 5.532

9.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

Authors:  U D Staerz; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  Preparation and biomedical applications of bispecific antibodies.

Authors:  H Paulus
Journal:  Behring Inst Mitt       Date:  1985-12
View more
  6 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.

Authors:  M V Pimm; R A Robins; R W Baldwin
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy.

Authors:  C Somasundaram; S Matzku; J Schuhmacher; M Zöller
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

4.  A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.

Authors:  Robert Mabry; Debra G Gilbertson; Amanda Frank; Tuyen Vu; Dan Ardourel; Craig Ostrander; Brenda Stevens; Susan Julien; Secil Franke; Brent Meengs; Jennifer Brody; Scott Presnell; Nels B Hamacher; Megan Lantry; Anitra Wolf; Tom Bukowski; Robert Rosler; Cindy Yen; Monica Anderson-Haley; Kenneth Brasel; Qi Pan; Hank Franklin; Penny Thompson; Mike Dodds; Sara Underwood; Scott Peterson; Pallavur V Sivakumar; Mark Snavely
Journal:  MAbs       Date:  2010-01-02       Impact factor: 5.857

5.  Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Yukiko Okuyama-Nishida; Chifumi Moriyama; Tetsuya Wakabayashi; Eriko Tanaka; Atsushi Muto; Tetsuo Kojima; Takehisa Kitazawa; Kazutaka Yoshihashi; Aya Harada; Miho Funaki; Kenta Haraya; Tatsuhiko Tachibana; Sachiyo Suzuki; Keiko Esaki; Yoshiaki Nabuchi; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

6.  Neisseria gonorrhoeae Multivalent Maxibody with a Broad Spectrum of Strain Specificity and Sensitivity for Gonorrhea Diagnosis.

Authors:  Jieun Jeong; Jae-Seok Kim; Junghyeon Lee; Yu Ri Seo; Eugene C Yi; Kristine M Kim
Journal:  Biomolecules       Date:  2021-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.